Holen Sie sich die Stockscreener-App
76.40
0.30%
0.23
Handel nachbörslich:
76.31
-0.09
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$76.17
Offen:
$75.69
24-Stunden-Volumen:
10.77M
Relative Volume:
0.69
Marktkapitalisierung:
$191.84B
Einnahmen:
$63.92B
Nettoeinkommen (Verlust:
$17.43B
KGV:
11.12
EPS:
6.87
Netto-Cashflow:
$17.04B
1W Leistung:
-1.85%
1M Leistung:
-9.81%
6M Leistung:
-24.83%
1J Leistung:
-39.32%
1-Tages-Spanne:
$75.69
$77.00
1-Wochen-Bereich:
$75.59
$78.20
52-Wochen-Spanne:
$73.31
$134.63
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Vergleichen Sie MRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
76.40 | 195.46B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
722.57 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.58 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.62 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
112.58 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
69.46 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Transcript : Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03 - marketscreener.com
Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS - insights.citeline.com
Merck & Co To Present At Bernstein Strategic Decisions Conference; Webcast At 3:30 PM ET - Nasdaq
Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer - Reuters
Merck & Co. Concludes Annual Shareholders Meeting - TipRanks
Merck shareholders approve board, executive pay at annual meeting By Investing.com - Investing.com India
Merck shareholders approve board, executive pay at annual meeting - Investing.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Merck, Daiichi pull approval application for ADC in lung cancer - BioPharma Dive
Merck: voluntary withdrawal of a BLA in lung cancer - marketscreener.com
Is Merck Stock Underperforming the Nasdaq? - MSN
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck (MRK) and Daiichi Sankyo Withdraw U.S. Application for Lung Cancer Therapy - GuruFocus
Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw - marketscreener.com
Merck (MRK) Withdraws Biologics License Application for Patritum - GuruFocus
Merck stock drops as BLA for lung cancer drug is pulled (MRK) - Seeking Alpha
Merck Withdraws Biologics License Application for Patritumab Deruxtecan - marketscreener.com
Major Setback: Merck's Advanced Lung Cancer Drug Falls Short in Crucial Survival Trial - Stock Titan
Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - Insider Monkey
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - Yahoo Finance
Abbisko Secures $85 Million from Merck for Pimicotinib Global Rights - TipRanks
Dow falls nearly 250 points on losses in Merck, Nike shares - MSN
Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight - PR Newswire UK
Merck Votes Overwhelmingly in Support of DEI Amid Backlash - Sustainability Magazine
Is Merck Stock Underperforming The Nasdaq? - Barchart.com
Merck Proves Why It’s Still A Top Pharma Pick (NYSE:MRK) - Seeking Alpha
Merck (MRK) Options Activity Highlights Bullish Sentiment | MRK Stock News - GuruFocus
Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2025, Payable on July 8, 2025 - marketscreener.com
Merck sets $0.81 quarterly dividend for Q3 2025 By Investing.com - Investing.com India
Merck Announces Third-Quarter 2025 Dividend - BioSpace
Merck Announces Third-Quarter 2025 Dividend Of $0.81 Per Share - marketscreener.com
NLPC Warns Merck About ‘Materially Misleading’ Shareholders on DEI - National Legal And Policy Center
Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors - GlobeNewswire Inc.
Merck & Co.’s SWOT analysis: stock faces keytruda LOE, china challenges - Investing.com
Merck Issues Statement On Potential Reduced Dosing Recommendation For Gardasil 9 - marketscreener.com
Merck: Dividend Near A 12-Year High, But I Won't BuyHere's Why (NYSE:MRK) - Seeking Alpha
Merck: Defensive Yield Meets Long-Term Optionality - Seeking Alpha
Merck (MRK) Advises Against Changing Gardasil Dosing Schedule - GuruFocus
Merck contends single dosing of Gardasil vaccine should be avoided - Seeking Alpha
Merck (MRK) Stands Firm on Gardasil 9 Dosing Standards | MRK Stock News - GuruFocus
Merck: Undervalued In Light Of Key Risks (NYSE:MRK) - Seeking Alpha
Merck & Co. Stock: Inventory Doesn’t Lie (NYSE:MRK) - Seeking Alpha
July 3rd Options Now Available For Merck (MRK) - Nasdaq
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference - BioSpace
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Merck and imec to develop a disruptive MicroPhysiological Systems platform - New Electronics
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Merck (NYSE:MRK) Collaborates With Antengene For Promising Cancer Therapy Evaluation - Yahoo Finance
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab) - BioSpace
Chloramine B Market to Witness Massive Growth by 2032 | Merck & Co., Inc., Anhui BBCA Pharmaceuticals Co., Ltd - openPR.com
Merck & Co., Inc.'s (NYSE:MRK) CEO Will Probably Find It Hard To See A Huge Raise This Year - simplywall.st
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):